Outstanding treatment for aesthetic indications and fat disorders About Raziel Therapeutics Raziel Therapeutics is a clinical-stage pharmaceutical company developing RZL-012, an injectable treatment for aesthetics and a variety of fat disorders. A single treatment session in which RZL-012 is injected into subcutaneous fat, results in significant and sustained reduction in fat volume. Read More About…
Location: Israel, Center District, Rehovot
Total raised: $22M
Investors 2
| Date | Name | Website |
| - | Quark Vent... | quarkventu... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.12.2019 | Series C | $22M | - |
Mentions in press and media 2
| Date | Title | Description |
| 04.03.2025 | Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma) Initiate Phase 3 Registration Trial in China for Submental Fat Reduction ("double chin") | REROVOT, Israel, March 4, 2025 /PRNewswire/ -- Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phase 3 study initiation in China for the treat... |
| 19.12.2019 | Raziel Therapeutics Raises $22M in Series C Funding | Raziel Therapeutics, a Rehovot, Israel-based clinical-stage pharmaceutical company, raised $22m in Series C financing. The round was led by Pontifax, with participation from existing investors Dr. Shmuel Cabilly and Docor International and ... |